▷ Galapagos Dividends 【Calendar 2024】

Upcoming Galapagos dividend

Change(%)

0.00%

No change

Next payment N/A

Next payment date N/A

Last payment N/A

Last payment date N/A

00 D 00 H 00 M 00 S

Ex-Dividend: N/A

Not available

When are the upcoming Galapagos dividends in 2024?

▶

Galapagos has not insinuated a dividend policy for 2024.

Dividend policy of Galapagos

▶

Galapagos N.V., listed on the Amsterdam Stock Exchange under the symbols GLPG, does not pay dividends to its shareholders and so far the company has not provided information on a change in this policy in the short term.

Payout Ratio Galapagos Dividends

In the last fiscal period, Galapagos paid no dividends, resulting in a dividend payout ratio of 0%.

Galapagos has not distributed dividends in the last fiscal period, therefore, the payout ratio is 0%.

Dividend payout ratio Payout Ratio

Dividend calendar of Galapagos

There is no Dividend Calendar of Galapagos defined for 2024.

Information about Galapagos

Full name Galapagos NV

Ticker GLPG

Sector Health Care

Industry Biotechnology

Market Capitalization 1.56B €

ISIN BE0003818359

Number of Employees 1,338

Description of the company

Galapagos N.V., is a Belgian company dedicated to research issues related to the development of medicines and drugs for the treatment of Crohn's disease, rheumatoid arthritis, psoriasis, ulcerative colitis, cystic fibrosis and systemic lupus erythematosus.

The purpose of the organization is to seek quality of life for its patients through the use of biotechnology, offering its clients the development and commercialization of drugs covering immunological procedures, oncological therapies, cellular therapies and others.

It was founded in 1999 through a partnership between Crucell and Tibotec, starting to be listed on Euronext Brussels and Amsterdam in 2005, extending its operations to France the following year, they bought and sold some other companies, but as of 2014 it focuses solely on its current research and development line.

In 2020 they receive authorization to market Jyseleca®, a drug for rheumatoid arthritis, which can be distributed and sold in the European Union, Japan and Great Britain, getting the following year another permit to market its drug against ulcerative colitis.

In 2022 they acquired CellPoint and AboundBio, thus diversifying their activities into next-generation cell therapy, achieving a therapeutic platform based on the use of human antibodies.

Their headquarters are located in Belgium, although they are located in the Netherlands, Germany, Italy, France, Switzerland, Austria, the United Kingdom, the Nordic countries and the United States, with more than 1,200 employees.